Business
Bioasis to Present at the OTC Markets 2020 Virtual Investor Conference
Bioasis to Present at the OTC Markets 2020 Virtual Investor Conference.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n\n\n\nBioasis to Present at the OTC Markets 2020 Virtual Investor Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nBioasis to Present at the OTC Markets 2020 Virtual Investor Conference\nPR Newswire\nGUILFORD, CONN., Feb. 19, 2020\n\n\n\nGUILFORD, CONN., Feb. 19, 2020 /PRNewswire/ -- Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the \"Company\" or \"Bioasis\"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (\"BBB\") and the treatment of central nervous system (\"CNS\") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that Dr. Deborah Rathjen, Executive Chair and Chief Executive Officer of Bioasis will present at the OTC Virtual Investor Conference.\nOTC Markets 2020 Virtual Investor Conference (February 20, 2020)Bioasis company presentation on Thursday, February 20, 2020 at 11:30 a.m. ET. Please register or login at the Virtual Investor Conferences website to view the presentation. This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. \nFollow @BioasisUS on TwitterFollow Bioasis on LinkedIn\nBTI-E&P\nAbout BioasisBioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., Un...